Research Analysts Issue Forecasts for ABVX FY2025 Earnings

ABIVAX Société Anonyme (NASDAQ:ABVX) – Analysts at Leerink Partnrs dropped their FY2025 earnings per share (EPS) estimates for ABIVAX Société Anonyme in a report issued on Monday, March 24th. Leerink Partnrs analyst T. Smith now expects that the company will post earnings per share of ($3.36) for the year, down from their previous forecast of ($3.00). The consensus estimate for ABIVAX Société Anonyme’s current full-year earnings is ($2.83) per share. Leerink Partnrs also issued estimates for ABIVAX Société Anonyme’s FY2026 earnings at ($3.25) EPS, FY2027 earnings at ($2.91) EPS, FY2028 earnings at ($2.31) EPS and FY2029 earnings at ($0.26) EPS.

Other research analysts have also issued research reports about the stock. Morgan Stanley reaffirmed an “equal weight” rating and set a $12.00 target price on shares of ABIVAX Société Anonyme in a research note on Thursday, March 20th. Citizens Jmp upgraded shares of ABIVAX Société Anonyme to a “strong-buy” rating in a research note on Wednesday, December 4th. Finally, JMP Securities reaffirmed a “market outperform” rating and set a $33.00 price target on shares of ABIVAX Société Anonyme in a report on Friday, January 10th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, ABIVAX Société Anonyme presently has an average rating of “Buy” and a consensus price target of $38.00.

ABIVAX Société Anonyme Stock Down 5.7 %

Shares of ABIVAX Société Anonyme stock opened at $6.43 on Thursday. The business’s fifty day simple moving average is $6.80 and its 200-day simple moving average is $8.37. ABIVAX Société Anonyme has a 52 week low of $5.50 and a 52 week high of $16.63.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Kennedy Capital Management LLC lifted its position in ABIVAX Société Anonyme by 0.7% in the fourth quarter. Kennedy Capital Management LLC now owns 225,470 shares of the company’s stock valued at $1,650,000 after acquiring an additional 1,656 shares during the last quarter. Bank of America Corp DE lifted its holdings in shares of ABIVAX Société Anonyme by 56.1% in the 4th quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock valued at $41,000 after purchasing an additional 1,990 shares during the last quarter. GAMMA Investing LLC acquired a new stake in shares of ABIVAX Société Anonyme in the 4th quarter valued at about $29,000. R Squared Ltd purchased a new position in ABIVAX Société Anonyme during the 4th quarter worth approximately $36,000. Finally, BNP Paribas Financial Markets increased its position in ABIVAX Société Anonyme by 82.6% during the third quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company’s stock worth $150,000 after buying an additional 5,900 shares during the period. 47.91% of the stock is owned by hedge funds and other institutional investors.

About ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.